AZN Stock Recent News
AZN LATEST HEADLINES
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic. "This country [the U.S.] will represent, we hope, 50% of our revenue by 2030," Soriot said Tuesday.
AstraZeneca Plc AZN on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2025 % Change Q2 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11 Reported EPS ($) 3.46 31 32 1.58 27 31 Core3 EPS ($) 4.66 16 17 2.17 10 12 Key performance elements for H1 2025 (Growth numbers at constant exchange.
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline. The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.
AstraZeneca share price held steady this week after the company published strong financial results on Tuesday. AZN stock was trading at 10,790p, a range it has remained in the past few days.
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket trading.
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.